Biotech M&A Wave Positions SBIO for Growth

Core Insights - The biotech M&A market is experiencing significant growth as pharmaceutical companies face a patent cliff that could result in a loss of $200 billion to $250 billion in branded medicine sales by 2032 [1] - A projected 15% increase in both the number of acquisitions and total deal value is expected by 2026, with approximately 520 transactions totaling $230 billion [1] - Investors are encouraged to focus on mid-cap biotech companies with drugs in advanced clinical trials, as 80% of expected deals will target these more advanced treatments [1] Biotech Fund Overview - The ALPS Medical Breakthroughs ETF (SBIO) is positioned to benefit from this M&A wave, holding companies that have at least one drug in Phase II or Phase III FDA clinical trials [1] - SBIO's portfolio includes 87 holdings with a total of 205 drugs in Phase II trials and 118 in Phase III trials [1] Market Opportunities - Major chronic disease markets such as diabetes and kidney disease are highlighted, with 589 million people living with diabetes and 850 million affected by kidney disease globally [1] - SBIO includes companies like MannKind Corporation, which reported fourth-quarter revenue exceeding $100 million, and others focused on obesity and rare kidney diseases [1] Performance Metrics - SBIO has achieved a 58.5% gain over the past year, outperforming all ALPS ETF products for 2025 [1] - The fund ended December with $141.9 million in assets under management and has a 0.50% expense ratio [1] Market Conditions - Reduced uncertainty in the U.S. market is noted following pricing agreements with branded pharmaceutical companies, alongside expected Federal Reserve rate cuts in 2026 that will lower acquisition costs [1]